These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 7600652)

  • 1. Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium.
    Hosenpud JD; Everett JP; Morris TE; Mauck KA; Shipley GD; Wagner CR
    Circulation; 1995 Jul; 92(2):205-11. PubMed ID: 7600652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal reduction in acute rejection after heart transplantation is not associated with a reduction in cell-mediated responses to donor-specific vascular endothelium.
    Hosenpud JD; Shipley GD; Mauck KA; Morris TE; Wagner CR
    J Heart Lung Transplant; 1995; 14(5):926-37. PubMed ID: 8800729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac allograft vasculopathy. Preferential regulation of endothelial cell-derived mesenchymal growth factors in response to a donor-specific cell-mediated allogeneic response.
    Hosenpud JD; Morris TE; Shipley GD; Mauck KA; Wagner CR
    Transplantation; 1996 Mar; 61(6):939-48. PubMed ID: 8623164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac allograft vasculopathy: IgM antibody responses to donor-specific vascular endothelium.
    Hosenpud JD; Mauck KA; Hogan KB
    Transplantation; 1997 Jun; 63(11):1602-6. PubMed ID: 9197353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
    Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
    Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of immune markers in human cardiac allograft recipients and association with coronary artery vasculopathy.
    Poggio ED; Roddy M; Riley J; Clemente M; Hricik DE; Starling R; Young JB; Gus B; Yamani MH; Heeger PS
    J Heart Lung Transplant; 2005 Oct; 24(10):1606-13. PubMed ID: 16210137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
    Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
    J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation.
    Fredrich R; Toyoda M; Czer LS; Galfayan K; Galera O; Trento A; Freimark D; Young S; Jordan SC
    Transplantation; 1999 Feb; 67(3):385-91. PubMed ID: 10030283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against heterogeneous nuclear ribonucleoprotein K in patients with cardiac allograft vasculopathy.
    Acevedo MJ; Caro-Oleas JL; Álvarez-Márquez AJ; Sobrino JM; Lage-Gallé E; Aguilera I; Núñez-Roldán A
    J Heart Lung Transplant; 2011 Sep; 30(9):1051-9. PubMed ID: 21489814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac allograft vasculopathy: a review.
    Weis M; von Scheidt W
    Circulation; 1997 Sep; 96(6):2069-77. PubMed ID: 9323100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients.
    Kalache S; Dinavahi R; Pinney S; Mehrotra A; Cunningham MW; Heeger PS
    J Immunol; 2011 Jul; 187(2):1023-30. PubMed ID: 21677143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tolerance induction and prevention of cardiac allograft vasculopathy in miniature swine: the effect of augmentation of donor antigen load.
    Yamada K; Mawulawde K; Menard MT; Shimizu A; Aretz HT; Choo JK; Allison KS; Slisz JK; Sachs DH; Madsen JC
    J Thorac Cardiovasc Surg; 2000 Apr; 119(4 Pt 1):709-19. PubMed ID: 10733759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
    Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for antibodies to human leukocyte antigens, collagen-V, and K-α1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy.
    Nath DS; Tiriveedhi V; Basha HI; Phelan D; Moazami N; Ewald GA; Mohanakumar T
    Transplantation; 2011 May; 91(9):1036-43. PubMed ID: 21383658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility.
    Costanzo-Nordin MR
    J Heart Lung Transplant; 1992; 11(3 Pt 2):S90-103. PubMed ID: 1623009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Functional Profiling of CD16-Dependent Natural Killer Activation Identifies Patients at Higher Risk of Cardiac Allograft Vasculopathy.
    Paul P; Picard C; Sampol E; Lyonnet L; Di Cristofaro J; Paul-Delvaux L; Lano G; Nicolino-Brunet C; Ravis E; Collart F; Dignat-George F; Dussol B; Sabatier F; Mouly-Bandini A
    Circulation; 2018 Mar; 137(10):1049-1059. PubMed ID: 29097449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
    Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR
    J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.